Physician profile
Anna S Robak
NPI 1336563808
$8,594.46
in general payments reported to CMS, 2019-2025
19 companies · $772 in 2025
The $772 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,019 · 2022: $3,053 · 2023: $2,849 · 2024: $902 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,518 · Travel and Lodging: $1,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,517.72 |
| Travel and Lodging | $1,005.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,644.49 | 2021-2025 | Lux-Dx Insertable Cardiac Monitor, Endotak Reliance S, Acuity Steerable |
| Medtronic, INC. | $2,843.57 | 2022-2025 | Linq II |
| E.R. Squibb & Sons, L.L.C. | $442.07 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $391.24 | 2021-2025 | Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $181.51 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $150.78 | 2022-2023 | Verquvo |
| Scpharmaceuticals INC. | $149.12 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $146.57 | 2021-2022 | |
| Abbott Laboratories | $139.91 | 2022-2024 | Jot Dx |
| Biotronik INC. | $81.14 | 2021 | |
| Amgen INC. | $79.90 | 2022-2023 | Repatha |
| Pfizer INC. | $78.37 | 2022-2024 | |
| Kestra Medical Technology Services, INC. | $65.02 | 2025 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $62.15 | 2023 | Optimizer |
| Philips North America LLC | $37.91 | 2022-2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.68 | 2024 | Jardiance |
| Novo Nordisk INC | $22.42 | 2023 | Ozempic |
| Lexicon Pharmaceuticals, INC. | $22.31 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $22.30 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Robak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.